NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

At the point that LP decided to invest massively in DCVax-L mfg infrastructure she created a "Failure is not an Option" situation. In that situation, a logical change to the trial would be to trade the alpha spend that would normally be used on early looks at efficacy for defining new subgroups.

I said this before but also speculated that some whiff of marginal efficacy might have been part of the motive. Just want to point out that this is not necessary. The sequence of events makes total sense without such a whiff.

That is... if such a trade in alpha spend is allowable. Not my forte'.

My impression is that there is some alpha spend allowed before it begins to raise the bar for approval. If so, it may have been within that initial allowance that they maneuvered.

But again... I don't know much about such things. Just hazy recollection of what others have said on this message board.